Resistance to rifampicin: At the crossroads between ecological, genomic and medical concerns

International Journal of Antimicrobial Agents

Volumn 35, Issue 6, 2010, Pages 519-523

  Tupin, Audrey ^a   Gualtieri, Maxime ^a   Roquet Banères, Françoise ^a   Morichaud, Zakia ^a   Brodolin, Konstantin ^a   Leonetti, Jean Paul ^a  

^a University of Montpellier I and II   (France)

Author keywords

Antibiotic; Bacterial ecology; Rifampicin resistance; Transcription

Indexed keywords

ANSAMYCIN DERIVATIVE; BINDING PROTEIN; RIFABUTIN; RIFALAZIL; RIFAMPICIN; RIFAMPICIN DERIVATIVE; RIFAMYCIN; RIFAPENTINE; RIFAXIMIN; RNA POLYMERASE;

ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; AUTOREGULATION; BIOFILM; CELL MEMBRANE PERMEABILITY; DRUG STRUCTURE; ECOLOGY; ENZYME INHIBITION; GENE MUTATION; GENOMICS; LEPROSY; NONHUMAN; PRIORITY JOURNAL; SHORT SURVEY; SIGNAL TRANSDUCTION; TUBERCULOSIS;

ANTI-BACTERIAL AGENTS; BACTERIA; BACTERIAL INFECTIONS; DRUG RESISTANCE, BACTERIAL; ECOLOGY; GENES, BACTERIAL; HUMANS; RIFAMPIN; SELECTION, GENETIC;

EID: 77951768374     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2009.12.017     Document Type: Short Survey

References (49)

1. Sensi P., Greco A.M., Ballotta R. Rifomycin I. Isolation and properties of rifomycin B and rifomycin complex. Antibiot Annu 1959, 7:262-270.
2. Sensi P., Ballotta R., Greco M. Rifomycin V, Rifomycin O. A new antibiotic of the rifomycin family. Farmaco Sci 1960, 15:228-234.
3. Gardner M.J., Williamson D.H., Wilson R.J.M. A circular DNA in malaria parasites encodes an RNA polymerase like that of prokaryotes and chloroplasts. Mol Biochem Parasitol 1991, 44:115-123.
4. Pukrittayakamee S., Viravan C., Charoenlarp P., Yeamput C., Wilson R.J., White N.J. Antimalarial effects of rifampin in Plasmodium vivax malaria. Antimicrob Agents Chemother 1994, 38:511-514.
5. Yim G., Huimi H.H., Davies J. Antibiotics as signalling molecules. Philos Trans R Soc Lond B Biol Sci 2007, 362:1195-1200.
6. Villain-Guillot P., Bastide L., Gualtieri M., Leonetti J.-P. Progress in targeting bacterial transcription. Drug Discov Today 2007, 12:200-208.
7. Campbell E.A., Korzheva N., Mustaev A., Murakami K., Nair S., Goldfarb A., et al. Structural mechanism for rifampicin inhibition of bacterial RNA polymerase. Cell 2001, 104:901-912.
8. Floss H.G., Yu T.W. Rifamycin-mode of action, resistance, and biosynthesis. Chem Rev 2005, 105:621-632.
9. m for purine nucleotides during transcription elongation. J Biol Chem 1991, 266:14478-14485.
10. Severinov K., Soushko M., Goldfarb A., Nikiforov V. Rifampicin region revisited. New rifampicin-resistant and streptolydigin-resistant mutants in the β subunit of Escherichia coli RNA polymerase. J Biol Chem 1993, 268:14820-14825.
11. R mutations in the beginning of the Escherichia coli rpoB gene. Mol Gen Genet 1994, 244:120-126.
12. Telenti A., Imboden P., Marchesi F., Lowrie D., Cole S., Colston M.J., et al. Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis. Lancet 1993, 341:647-650.
13. Ramaswamy S., Musser J.M. Molecular genetic basis of antimicrobial agent resistance in Mycobacterium tuberculosis: 1998 update. Tuber Lung Dis 1998, 79:3-29.
14. Heep M., Odenbreit S., Beck D., Decker J., Prohaska E., Rieger U., et al. Mutations at four distinct regions of the rpoB gene can reduce the susceptibility of Helicobacter pylori to rifamycins. Antimicrob Agents Chemother 2000, 44:1713-1715.
15. Heep M., Rieger U., Beck D., Lehn N. Mutations in the beginning of the rpoB gene can induce resistance to rifamycins in both Helicobacter pylori and Mycobacterium tuberculosis. Antimicrob Agents Chemother 2000, 44:1075-1077.
16. Heep M., Brandstatter B., Rieger U., Lehn N., Richter E., Rusch-Gerdes S., et al. Frequency of rpoB mutations inside and outside the cluster I region in rifampin-resistant clinical Mycobacterium tuberculosis isolates. J Clin Microbiol 2001, 39:107-110.
17. Perkins A.E., Nicholson W.L. Uncovering new metabolic capabilities of Bacillus subtilis using phenotype profiling of rifampin-resistant rpoB mutants. J Bacteriol 2008, 190:807-814.
18. Maguire B.A., Wild D.G. Identification of a mutation conferring antibiotic dependence in Escherichia coli. 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), 25-28 October 2008, Washington, DC 2008, 124. ASM Press, Washington, DC.
19. Sonenshein A.L., Cami B., Brevet J., Cote R. Isolation and characterization of rifampin-resistant and streptolydigin-resistant mutants of Bacillus subtilis with altered sporulation properties. J Bacteriol 1974, 120:253-265.
20. Kawamura N., Kurokawa K., Ito T., Hamamoto H., Koyama H., Kaito C., et al. Participation of Rho-dependent transcription termination in oxidative stress sensitivity caused by an rpoB mutation. Genes Cells 2005, 10:477-487.
21. Hu H., Zhang Q., Ochi K. Activation of antibiotic biosynthesis by specified mutations in the rpoB gene (encoding the RNA polymerase β subunit) of Streptomyces lividans. J Bacteriol 2002, 184:3984-3991.
22. Bergval I.L., Klatser P.R., Schuitema A.R.J., Oskam L., Anthony R.M. Specific mutations in the Mycobacterium tuberculosis rpoB gene are associated with increased dnaE2 expression. FEMS Microbiol Lett 2007, 275:338-343.
23. Jin D.J., Walter W.A., Gross C.A. Characterization of the termination phenotypes of rifampicin-resistant mutants. J Mol Biol 1988, 202:245-253.
24. Adone R., Ciuchini F., Marianelli C., Tarantino M., Pistoia C., Marcon G., et al. Protective properties of rifampin-resistant rough mutants of Brucella melitensis. Infect Immun 2005, 73:4198-4204.
25. Björkman J., Hughes D., Andersson D.I. Virulence of antibiotic-resistant Salmonella typhimurium. Proc Natl Acad Sci USA 1998, 95:3949-3953.
26. Gagneux S., Long C.D., Small P.M., Van T., Schoolnik G.K., Bohannan B.J.M. The competitive cost of antibiotic resistance in Mycobacterium tuberculosis. Science 2006, 312:1944-1946.
27. Enne V.I., Delsol A.A., Roe J.M., Bennett P.M. Rifampicin resistance and its fitness cost in Enterococcus faecium. J Antimicrob Chemother 2004, 53:203-207.
28. Kageyama A., Yazawa K., Ishikawa J., Hotta K., Nishimura K., Mikami Y. Nocardial infections in Japan from 1992 to 2001, including the first report of infection by Nocardia transvalensis. Eur J Epidemiol 2004, 19:383-389.
29. Schaal K.P., Lee H.-J. Actinomycete infections in humans-a review. Gene 1992, 115:201-211.
30. Wauters G., Avesani V., Charlier J., Janssens M., Vaneechoutte M., Delmee M. Distribution of Nocardia species in clinical samples and their routine rapid identification in the laboratory. J Clin Microbiol 2005, 43:2624-2628.
31. Ishikawa J., Yamashita A., Mikami Y., Hoshino Y., Kurita H., Hotta K., et al. The complete genomic sequence of Nocardia farcinica IFM 10152. Proc Natl Acad Sci USA 2004, 101:14925-14930.
32. Ishikawa J., Chiba K., Kurita H., Satoh H. Contribution of rpoB2 RNA polymerase β subunit gene to rifampin resistance in Nocardia species. Antimicrob Agents Chemother 2006, 50:1342-1346.
33. Vigliotta G., Tredici S.M., Damiano F., Montinaro M.R., Pulimeno R., di Summa R., et al. Natural merodiploidy involving duplicated rpoB alleles affects secondary metabolism in a producer actinomycete. Mol Microbiol 2005, 55:396-412.
34. Inaoka T., Takahashi K., Yada H., Yoshida M., Ochi K. RNA polymerase mutation activates the production of a dormant antibiotic 3,3′-neotrehalosadiamine via an autoinduction mechanism in Bacillus subtilis. J Biol Chem 2004, 279:3885-3892.
35. Newell K.V., Thomas D.P., Brrekasis D., Paget M.S. The RNA polymerase-binding protein RbpA confers basal levels of rifampicin resistance on Streptomyces coelicolor. Mol Microbiol 2006, 60:687-696.
36. Hu Y., Mangan J.A., Dhillon J., Sole K.M., Mitchison D.A., Butcher P.D., et al. Detection of mRNA transcripts and active transcription in persistent Mycobacterium tuberculosis induced by exposure to rifampin or pyrazinamide. J Bacteriol 2000, 182:6358-6365.
37. Pomerantz R.T., O'Donnell M. The replisome uses mRNA as a primer after colliding with RNA polymerase. Nature 2008, 456:762-766.
38. Flåtten I., Morigen K., Morigen S. DnaA protein interacts with RNA polymerase and partially protects it from the effect of rifampicin. Mol Microbiol 2009, 71:1018-1030.
39. Wegrzyn A., Szalewska-Palasz A., Blaszczak A., Liberek K., Wegrzyn G. Differential inhibition of transcription from sigma70- and sigma32-dependent promoters by rifampicin. FEBS Lett 1998, 440:172-174.
40. Vassylyev D.G., Vassylyeva M.N., Perederina A., Tahirov T.H., Artsimovitch I. Structural basis for transcription elongation by bacterial RNA polymerase. Nature 2007, 448:157-162.
41. Imai T., Watanabe K., Mikami Y., Yazawa K., Ando A., Nagata Y., et al. Identification and characterization of a new intermediate in the ribosylative inactivation pathway of rifampin by Mycobacterium smegmatis. Microb Drug Resist 1999, 5:259-264.
42. Combrink K.D., Denton D.A., Harran S., Ma Z., Chapo K., Yan D., et al. New C25 carbamate rifamycin derivatives are resistant to inactivation by ADP-ribosyl transferases. Bioorg Med Chem Lett 2007, 17:522-526.
43. Dabbs E., Yazawa K., Tanaka Y., Mikami Y., Miyaji M., Andersen S., et al. Rifampicin inactivation by Bacillus species. J Antibiot (Tokyo) 1995, 48:815-819.
44. Tanaka Y., Yazawa K., Dabbs E., Nishikawa K., Komaki H., Mikami Y., et al. Different rifampicin inactivation mechanisms in Nocardia and related taxa. Microbiol Immunol 1996, 40:1-4.
45. Hui J., Gordon N., Kajioka R. Permeability barrier to rifampin in mycobacteria. Antimicrob Agents Chemother 1977, 11:773-779.
46. Siddiqi N., Das R., Pathak N., Banerjee S., Ahmed N., Katoch V.M., et al. Mycobacterium tuberculosis isolate with a distinct genomic identity overexpresses a tap-like efflux pump. Infection 2004, 32:109-111.
47. Fernandes P., Ferreira B.S., Cabral J.M.S. Solvent tolerance in bacteria: role of efflux pumps and cross-resistance with antibiotics. Int J Antimicrob Agents 2003, 22:211-216.
48. Maness M., Sparling P. Multiple antibiotic resistance due to a single mutation in Neisseria gonorrhoeae. J Infect Dis 1973, 128:321-330.
49. Hagman K., Pan W., Spratt B., Balthazar J., Judd R., Shafer W. Resistance of Neisseria gonorrhoeae to antimicrobial hydrophobic agents is modulated by the mtrRCDE efflux system. Microbiology 1995, 141:611-622.